Chronic Obstructive Pulmonary Disease
📧 Sign up to get email alerts when something new happens for Chronic Obstructive Pulmonary Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-05-29FDA Approved: STIOLTO RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for STIOLTO RESPIMAT (tiotropium bromide and olodaterol) submitted by Boehringer Ingelheim Pharm…
-
FDA approval · 2019-05-29FDA Approved: BEVESPI AEROSPHERE — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) by AstraZeneca Pharmaceuticals LP.
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [Phase 3]
A Phase 3 trial compared the efficacy and safety of a glycopyrronium/formoterol fumarate fixed-dose combination versus umeclidinium/vilanter…
-
FDA approval · 2019-05-21FDA Approved: YUPELRI — Supplemental Application (Viatris Specialty LLC)
The FDA approved Viatris Specialty LLC's supplemental application for YUPELRI (revefenacin), expanding its approved labeling.
-
FDA approval · 2019-05-15FDA Approved: TRELEGY ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)
The FDA approved a supplemental application for TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) from GlaxoSmithKline LLC, with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-05-15Clinical Trial Update: Smoking Relapse Prevention Among COPD Ex-smokers [Phase 3]
Phase 3 trial on smoking relapse prevention among COPD ex-smokers was terminated.
-
CLINICAL_TRIALS trial_result · 2019-05-14Clinical Trial Update: Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance [Phase 4]
Phase 4 trial evaluating the effect of nocturnal oxygen on exercise performance in COPD patients at altitude.
-
CLINICAL_TRIALS trial_result · 2019-05-14Clinical Trial Update: Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude [Phase 4]
Phase 4 clinical trial evaluating the effect of acetazolamide on cognition in COPD patients at altitude has completed.
-
CLINICAL_TRIALS trial_result · 2019-04-29Clinical Trial Update: Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD [Phase 4]
Phase 4 trial comparing QVA149 to tiotropium plus salmeterol/fluticasone in moderate to severe COPD; results completed with posted data in 2…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: Beta Blocker Therapy in Moderate to Severe COPD [Phase 4]
Phase 4 clinical trial update on beta blocker therapy in moderate to severe chronic obstructive pulmonary disease has completed.
-
CLINICAL_TRIALS trial_result · 2019-04-22Clinical Trial Update: The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants [NA]
A terminated clinical trial evaluating high frequency oscillations with noninvasive ventilation in hypercapnic COPD participants has posted …
-
CLINICAL_TRIALS trial_result · 2019-04-18Clinical Trial Update: Study of Danirixin in Japanese Healthy Elderly Male Subjects [Phase 1]
Phase 1 study of danirixin in Japanese healthy elderly male subjects completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-04-17Clinical Trial Update: Assessment of Reactance Parameters Measured by the Forced Oscillation Technique for the Bronchodilator Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
Phase 4 clinical trial investigating reactance parameters from forced oscillation technique to assess bronchodilator response in COPD patien…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)
Clinical trial update for OTIVACTO (tiotropium/olodaterol) in COPD assessing physical functioning and handling; study terminated with result…
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients [NA]
A completed pilot clinical trial for Vitabreath in COPD patients with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-04-12Clinical Trial Update: Does Extra-fine Hydrofluoroalkane-beclomethasone Dipropionate (HFA-BDP) Suppress Small Airways Inflammation in Chronic Obstructive Pulmonary Disease (COPD)? [Phase 4]
A Phase 4 trial investigating whether extra-fine HFA-beclomethasone dipropionate reduces small airway inflammation in COPD has completed.
-
CLINICAL_TRIALS trial_result · 2019-04-12Clinical Trial Update: Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
Phase 4 trial assessing the effects of roflumilast on subclinical atherosclerosis in COPD; study completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-04-12Clinical Trial Update: Evaluation of Long-Acting Muscarinic Antagonists in COPD [Phase 4]
Phase 4 trial update evaluating long-acting muscarinic antagonists in chronic obstructive pulmonary disease has completed.
-
CLINICAL_TRIALS trial_result · 2019-04-12Clinical Trial Update: Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]
A Phase 4 clinical trial reporting differential trough effects of a triple therapy on pulmonary function in COPD.
-
CLINICAL_TRIALS trial_result · 2019-04-10Clinical Trial Update: Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). [Phase 4]
Phase 4 trial comparing fluticasone furoate/vilanterol inhalation powder to vilanterol alone in COPD, focusing on bone mineral density outco…
-
CLINICAL_TRIALS trial_result · 2019-04-09Clinical Trial Update: A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease [Phase 4]
Phase 4 trial updating dose response for inhaled fluticasone propionate in chronic obstructive pulmonary disease completed with results post…
-
FDA approval · 2019-03-29FDA Approved: DUAKLIR PRESSAIR — Original Application (Covis Pharma US, Inc)
FDA approved Duaklir Pressair as an original-application fixed-dose inhaled therapy combining aclidinium bromide and formoterol fumarate for…
-
FDA approval · 2019-03-29FDA Approved: TUDORZA PRESSAIR — Supplemental Application (Covis Pharma US, Inc)
The FDA approved a supplemental application for Tudorza Pressair (aclidinium bromide) from Covis Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2019-03-29Clinical Trial Update: Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients [Phase 1]
Phase 1 trial examining the bioavailability of tiotropium + olodaterol fixed-dose combination in Chinese patients with chronic obstructive p…
-
CLINICAL_TRIALS trial_result · 2019-03-29Clinical Trial Update: Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep [Phase 4]
Phase 4 trial update comparing fluticasone-salmeterol in COPD, with results posted after completion.